Effector combining EFT508 and Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) will conduct an open-label, Phase II trial evaluating EFT508 with or without PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) in patients with microsatellite stable relapsed or refractory colorectal cancer (CRC). The companies plan to start the trial in 3Q17 and share clinical costs.

EFT508 is a small molecule inhibitor of MAP kinase interacting serine-threonine kinase 1 (MKNK1; MNK1) and MKNK2 (MNK2). It is in Phase I/II testing to treat advanced solid tumors and lymphoma...